Versartis, Inc. (NASDAQ:VSAR) Files An 8-K Other Events
Item 8.01
|
Other Events. |
On April 3, 2017, the Company announced that new data on
somavaratan in pediatric and adult GHD were presented during the
Endocrine Society’s 99th Annual Meeting Expo (ENDO 2017), being
held April 1-4, 2017 in Orlando, FL. A copy of the press release
regarding this announcement, titled Versartis Reports New Data on
Long-Acting Somavaratan in Growth Hormone Deficiency at ENDO 2017
is attached as Exhibit 99.1 hereto and is incorporated herein by
reference.
In addition, on April 3, 2017, the Company announced that
three-year safety and efficacy data on somavaratan in pediatric
GHD were presented during an oral session at ENDO 2017, held
April 1-4, 2017 in Orlando, FL. A copy of the press release
regarding this announcement, titled Versartis Announces Three
Year Somavaratan Data at ENDO 2017 Showing Safety and Efficacy in
Line with Historical U.S. Daily rhGH Data in Pediatric GHD is
attached as Exhibit 99.2 hereto and is incorporated herein by
reference.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits are furnished with this Current Report on
Form 8-K.
|
Exhibit No. |
Description |
||
|
99.1 |
Press release dated April 3, 2017, titled Versartis |
||
|
99.2 |
Press release dated April 3, 2017, titled Versartis |
||
About Versartis, Inc. (NASDAQ:VSAR)
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals. Versartis, Inc. (NASDAQ:VSAR) Recent Trading Information
Versartis, Inc. (NASDAQ:VSAR) closed its last trading session down -0.55 at 20.80 with 570,838 shares trading hands.
